Narmin Javadova

Dr. Narmin Javadova

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RDRachel Van Doorn
Rachel Van Doorn
NJNarmin Javadova
Narmin Javadova
IFIan P. Flyke
Ian P. Flyke
MLMichael R. Lasarev
Michael R. Lasarev
KKKyungMann Kim
KyungMann Kim
KHKara K. Hoppe
Kara K. Hoppe
Objective: To evaluate the effect of aspirin dose on the incidence of all gestational age preeclampsia and preterm preeclampsia. Data sources: Electronic databases (Cochrane, PubMed, Scopus, ClinicalTrials.gov and the Web of Science) were searched for articles published between January 1985 and March 2019 with no language restrictions. Methods: We followed the PRIMSA guidelines and utilized Covidence software. Articles were screened by 2 independent reviewers, with discrepancies settled by an independent 3rd party. Study selection criteria were randomized trials comparing aspirin for prevention of all gestational age and preterm preeclampsia to placebo or no antiplatelet treatment in women aged 15–55 years with moderate or high-risk factors according to the list of risk factors from American College of Obstetricians and Gynecologists and United States Preventive Services Task Force guidelines. The quality of trials was assessed using the Cochrane risk of bias tool. The data were pooled using a random-effects meta-analysis comparing aspirin at doses of <81, 81, 100, and 150 mg. Pre-specified outcomes were all gestational age and preterm preeclampsia. Results: Of 1,609 articles screened, 23 randomized trials, which included 32,370 women, fulfilled the inclusion criteria. In preterm preeclampsia, women assigned at random to 150 mg experienced a significant 62% reduction in risk of preterm preeclampsia (RR = 0.38; 95% CI: 0.20–0.72; P = 0.011). Aspirin doses <150 mg produced no significant reductions. The number needed to treat with 150 mg of aspirin was 39 (95% CI: 23–100). There was a maximum 30% reduction in risk of all gestational age preeclampsia at all aspirin doses. Conclusions: In this meta-analysis, based on indirect comparisons, aspirin at a dose greater than the current, recommended 81 mg was associated with the highest reduction in preterm preeclampsia. Our meta-analysis is limited due to the deficiency of homogeneous high evidence data available in the literature to date; however, it may be prudent for clinicians to consider that the optimal aspirin dose may be higher than the current guidelines advise. Future research to compare the efficacy aspirin doses greater than 81 mg is recommended. Study registration: PROSPERO, CRD42019127951 (University of York, UK; http://www.crd.york.ac.uk/PROSPERO/).


1 January 2021 in American Journal of Obstetrics & Gynecology MFM
Verified
Journal Article
Closed access
NJNarmin Javadova
Narmin Javadova
OAOguzhan Alagoz
Oguzhan Alagoz
YCYu-Hsin Chen
Yu-Hsin Chen
KHKara Hoppe
Kara Hoppe

31 January 2022 in The Journal of Pediatrics
Verified
Journal Article
Closed access
NJNarmin Javadova
Narmin Javadova
BHBarbara Ha
Barbara Ha
CDCarol A. Diamond
Carol A. Diamond
APAmy J. Plumb
Amy J. Plumb
PKPamela Kling
Pamela Kling

29 October 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
NJNarmin Javadova
Narmin Javadova
PKPamela Kling
Pamela Kling
SNSally Norlin
Sally Norlin
WHWhitley Nicholle Hulse
Whitley Nicholle Hulse
Objective: To implement a neonatal iron deficiency (ID) guideline as part of a neuroprotective strategy using reticulocyte hemoglobin content (RET-He) for neonates born <33 weeks postmenstrual age (PMA) and small for gestational age (SGA) neonates ≥33 weeks PMA, to achieve ≥80% screening rate by June 2024. Methods: An interdisciplinary team conducted a quality improvement initiative in a level III neonatal intensive care unit (NICU) from April 2022 to August 2024. RET-He is a validated, sensitive marker of early iron deficiency reflecting recent iron supply for erythropoiesis and providing a more reliable measure than ferritin. The primary outcome was RET-He screening at 30 ± 7 days for neonates <33 weeks PMA or pre-discharge for SGA neonates ≥33 weeks PMA. Exclusion criteria were death or transfer before eligibility. Process measures included ID screening failure rate (RET-He level < 29 pg). Results: Of 345 eligible neonates, P-chart analysis showed screening rates for premature neonates <33 weeks PMA declined during PDSA 1–2, before improving to 85.9% in PDSA 3. ID screening failure was 12.6% at one month, increasing to 32.1% at two months. For SGA neonates ≥33 weeks PMA, screening rates remained low, peaking at 36% in PDSA 3, with a 2.2% failure rate. Conclusions: Implementation of a RET-He based ID guideline improved screening rates for premature neonates but was less effective for SGA neonates. Despite improved guideline adherence, ID prevalence remained high at NICU discharge, indicating a further need to improve nutritional prevention and treatment strategies.